Muscle training is effective for improving motor function, although withdrawal within 3-6 months has been reported in many cases. Thus, we aimed to establish locomotion training recommended by the Japanese Orthopaedic Association and our own locomotive syndrome prevention training (herein after collectively referred to as “locomotive training”) as a daily routine. Subjects were 30 participants of a training course held in 2014. Nine sessions (including 1 follow-up session) were organized to repetitively teach the importance of locomotive training; participants were instructed to record daily training activities during the course. Duration of oneleg standing balance with eyes open was measured each session so that participants were aware of the effects of the training. At the time of the last session of the course and at the follow-up session, 90% and 83% of participants completed home training twice or three times a week, respectively. Participants reported physical changes such as amelioration of knee pain and ability to put on a Wellington boot while standing on one leg. Also, physical fitness tests performed before and after the course showed significant improvement on the Timed Up and Go test, 30-s chair stand test, and one-leg standing with eyes open after the training course. Furthermore, the locomotive syndrome test resulted in a decrease in the number of participants who were judged to have a possibility to suffer from locomotive syndrome. Taken together, introducing a cycle comprising the three components of motivation-building through lectures, increasing awareness by recording performance, and awareness of the training effect by measuring duration of one-leg standing balance contributed to training continuity and consequent improvement in motor function.

Oxycodone controlled-release (CR) tablets are used as a first-line opioid analgesic for cancer pain. However, use of oxycodone CR tablets is associated with toxicities such as drowsiness and constipation, leading to deterioration of the quality of life (QOL), especially in patients with gynecologic cancer. In contrast, fentanyl has a superior toxicity profile while still showing a strong analgesic effect. Although fentanyl has been approved for switching from opioid, there have been no Japanese studies of patients with gynecologic cancer who were switched to transdermal fentanyl after experiencing toxicity during therapy with oxycodone CR. More importantly early introduction of palliative therapy for pain has not been adopted routinely in the management of gynecologic cancer. Thus, it appears that treatment for patients with gynecologic cancer remains unsatisfactory at present. We conducted research into improvement of the toxicity profile and pain control with the aim of improving QOL for patients with gynecologic cancer. We showed that pain, drowsiness, and constipation could be significantly improved in gynecologic cancer patients as a result of switching to transdermal fentanyl therapy at an early stage.